Copy-cats of weight-loss drugs Ozempic and Wegovy are hurting Novo Nordisk

Denmark's farmer giant Novon Nordisk has a problem. Copycats. About 1 million patients in the US are using cheaper versions of its blockbuster weight loss and diabetes drugs.And it's hurting Noville's bottom line. The company has lost about 2/3 of its value in the past year, wiping out hundreds of billions of dollars. It's now slashed its earnings outlook for the second time this year, sending shares plunging 23% in a day.Norville's imitation problem stems from a failure to meet the demand for its drugs whi ...